tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Consun Pharmaceutical Reports Strong Interim Financial Results for 2025

Story Highlights
Consun Pharmaceutical Reports Strong Interim Financial Results for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Consun Pharmaceutical Group Ltd. ( (HK:1681) ) just unveiled an announcement.

Consun Pharmaceutical Group Ltd. reported a significant financial growth for the first half of 2025, with revenue increasing by 23.7% to RMB1,568,588,000 and profit attributable to equity shareholders rising by 24.6% to RMB498,299,000 compared to the same period in 2024. This strong performance is reflected in the declared interim dividend of HKD0.33 per share, indicating a positive outlook for stakeholders and reinforcing the company’s robust market positioning.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

More about Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development, manufacturing, and sale of pharmaceutical products.

Average Trading Volume: 2,561,143

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.09B

For an in-depth examination of 1681 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1